Postmarketing surveillance of adverse drug reactions: problems and solutions.
The surveillance of adverse drug reactions (ADRs) is an unqualified must. However, the optimal means of surveillance is still unclear. Although anecdotal reports are the backbone of an ADR surveillance system, they are not enough. The pharmaceutical industry, academics and regulatory agencies need to expand their efforts in monitoring ADRs. The author discusses the various techniques for counting and evaluating adverse reactions and suggests ways in which the system could be improved.
D002170:Canada; D064420:Drug-Related Side Effects and Adverse Reactions; D004739:England; D005069:Evaluation Studies as Topic / Q000379:methods*; D005602:France; D006077:Government Agencies; D006801:Humans; D007256:Information Systems; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D014481:United States